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dose might have been insufficient for a twin pregnancy), and
further studies will certainly be of great interest. However, I
do not think that this case supports the hypothesis of a deter-
minative role for beta-sympathomimetic drugs in fetal lung
maturation.
Service de Gyn&eacute;cologie Obst&eacute;trique,
H&ouml;pital Antoine Becl&egrave;re,
9240 Clamart, France LUCIEN SCHNEIDER
PRENATAL DIAGNOSIS OF MAROTEAUX-LAMY
SYNDROME
SIR,--The Maroteaux-Lamy syndrome, or mucopolysac-
charidosis type vi (M.P.S. vi), is an autosomal recessive dis-
order characterised by severe skeletal deformities, growth
retardation, and corneal opacity. The basic defect is a defi-
ciency of the lysosomal enzyme arylsulphatase B (A.S.B.).1
Both A.s.B deficiency2 and an accumulation of sulphated
mucopolysaccharides3 have been demonstrated in cultured
skin fibroblasts from ht.P.s. vi patients. Since A.s.B activity is
measurable in cultured amniotic-fluid cells4 prenatal diagnosis
should be possible.
We have investigated the second pregnancy of a woman
whose first child had M.P.S. vi, established by the demonstra-
tion of A.s.B deficiency in leucocytes (Dr K. 0. Liem, Free
ARYLSULPHATASE A AND B ACTIVITIES IN CULTURED AMNIOTIC-FLUID
CELLS AND FIBROBLASTS
*Average activity (nmol h-l mg ’ protein of triplicate determinations).
tCultures used in the analyses were matched for duration of cell-culture and
number of subcultures.
University, Amsterdam) and in cultured fibroblasts. Amnio-
centesis was done in the 16th week of pregnancy (Dr H. B.
Rethmeyer, Sophia Hospital, Zwolle) and amniotic-fluid cells
were cultured.5 After 16 days of growth, the cells were har-
vested, homogenised by sonication, and analysed for A.s.B acti-
vity using a micromodification of the method of Baum et al. 6
Only 5 jjd of cell homogenate (about 104 cells) was used per in-
cubation with 4-nitrocatechol sulphate as the substrate; the
amount of 4-nitrocatechol produced was measured in a final
volume of 55 &micro;l.7
The specific activities of A.s.B (table) showed a deficiency in
the amniotic-fluid cells from the pregnancy at risk as well as
in the fibroblasts from the index patient. The activities of
A.s.A, measured as a control lysosomal enzyme, seemed nor-
mal. Additional evidence, demonstrating that the fetus was
affected, was obtained from the study of 35S-sulphate incorpo-
ration into the intracellular mucopolysaccharide pools.8 After
1. Stumpf, D. A., Austin, J. H., Crocker, A. C., LaFrance, M. Am. J. Dis. Child.
1973, 126, 747.
2. Fluharty, A. L., Stevens, R. L., Sanders, D L., Kihara, H. Biochim. bio-
phys. Res. Commun. 1974, 59, 455.
3 Barton, R. W., Nuefeld, E. F. J. Pediatrics, 1972, 80, 114.
4. Beratis, N. G., Turner, B. M., Weiss, R., Hirschhorn, K. Pediat. Res. 1975,
9, 475.
5. Niermeijer, M. F., Koster, J. F., Jahodova, M., Fernandes, J., Heukels-
Dully, M. J., Galjaard, H. ibid. 1975, 9, 498.
6 Baum, H., Dodgson, K. S., Spencer, B. Clinica. Chim. Acta, 1959, 4, 453.
7. Galjaard, H., Hoogstraten, J. J. van, de Josselin de Jong, J. E., Mulder,
M. P. Histochem. J. 1974, 6, 409.
8. Fratantoni, J. C., Hall, C. W., Neufeld, E. F. Proc. natn. Acad. Sci. U.S.A.
1969, 64, 360.
4 days of incorporation, fibroblasts from the index patient and
amniotic-fluid cells from the pregnancy at risk showed a three-
fold raised level of labelled intracellular mucopolysaccharides
as compared with controls.
The parents decided on termination of pregnancy at the
20th week. Confirmatory studies were done on fetal liver and
skin by separation of A.s.A and A.s.B2 on a D.E.A.E.-column
and measurement of activities with 4-methylumbelliferyl sul-
phate as the substrate. In a control fetal liver 58% of the total
A.S. activity was found in the B peak. In contrast the A.s.B
activity in the liver of the affected fetus was reduced to 8% of
the total arylsulphatase activity. Similar results, confirming
A.s.B deficiency in this fetus, were obtained with the fetal skin.
These results demonstrate that a reliable prenatal diagnosis
ofM.p.s. vi is possible and can be completed within 2-3 weeks
after amniocentesis if microtechniques are used.
Dr J. J. M. van Gemund (University Hospital, Leiden), referred this
family. This study was financed in part by Het Praeventiefonds, the
Hague, Netherlands.
Department of Cell Biology and Genetics
Erasmus University Rotterdam,






CHOLINERGIC SIDE-EFFECTS ASSOCIATED WITH
DEANOL
SIR The drug deanol (2-dimethylaminoethanol) has been
reported to be useful in the management of several neurologi-
cal problems, including learning disorders and hyperkinesis of
childhood, levodopa-induced dyskinesias, Huntington’s
chorea, and some cases of tardive dyskinesia.1-3 Deanol is
thought to be effective in these conditions through its conver-
sion in vivo to choline and acetylcholine. High doses (above 1
g per day in adults) given for at least 3 weeks are required
before the efficacy of the drug can be determined.’ Side-effects
have not been prominent with this drug. We wish to report the
occurrence of serious cholinergic side-effects in one patient.
The patient was a 37-year-old woman who had tardive dys-
kinesia of 4 years’ duration, which had not responded to other
drugs. She had grotesque oral, lingual, and buccal movements
which had caused her to break several teeth and to bite her
tongue occasionally. These movements would cease tem-
porarily upon voluntary actions such as forced protrusion of
the tongue, but she experienced difficulty with chewing and
swallowing, and she would frequently spit rather than swallow
her saliva. Deanol was given for 19 days in increasing doses.
After 17 days, while receiving 1500 mg per day, the patient
began to have increased nasal and oral secretions. Within 2
more days she complained of dyspnoea and was having obvious
respiratory difficulty. Examination disclosed rhinorrhcea, sia-
lorrhoea, a respiratory-rate of 25/min, a pulse-rate of 100/min,
and unchanged blood-pressure. Diffuse rhonchi and moderate
expiratory wheezing were heard in both lung fields; many
upper airway sounds also were present. She was afebrile, and
a blood-count revealed no evidence of infection. A chest film
taken at the time showed only changes consistent with chronic
obstructive pulmonary disease (the woman was a heavy
smoker). Deanol was discontinued, and within 16 h the patient
reported improvement in her symptoms; objectively the lungs
had cleared considerably. By the second day after the drug was
stopped the lungs were clear, the rhinorrhoea and sialorrh&oelig;a
had stopped, and the patient had returned to her previous
status.
These side-effects of a cholinergic nature suggest that
deanol may indeed act in man by conversion to choline and
1. Re, O. Curr. ther. Res. 1974, 16, 1238.
2. Miller, E. M. New Engl. J. Med. 1974, 291, 796.
3. Escobar, J. I., Kemp, J. F. ibid. 1975, 292, 317.
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acetylcholine. The clinical picture was thought initially to be
one of bronchopneumonia; this was not the case but broncho-
pneumonia might well have developed had the drug been con-
tinued.
Neuropsychiatric Institute,
University of Michigan Medical Center,
University Hospital,
Ann Arbor, Michigan 48104, U.S.A.
RANDOLPH NESSE
BERNARD J. CARROLL
ACRODERMATITIS ENTEROPATHICA AND NERVE
DAMAGE
SIR,&mdash;Several reports have been published in The Lancet on
the &aelig;tiology,1 symptoms, 2 and treatment4 of acrodermatitis
enteropathica. Clearly long-term treatment with oxyquinoline
derivatives may be very dangerous because of damage to the
optic nerve. Its replacement by zinc leads to a complete and
quick recovery, becau se- according to our present know-
ledge-the disease is caused by zinc malabsorption.
In our experience in five patients biochemical investigations
and clinical observations confirm that zinc treatment is effec-
tive and safe. These patients had been on oxyquinolines
’Enteroseptol’ for months or even years, and none had optic-
nerve damage. But we did find hypoacusis in two of our pa-
tients during the treatment(one of them had had an antrotomy
operation as a baby). This might mean that the neurotoxic
effect of oxyquinoline products affects not only the optic nerve
but also the acoustic (cochlear) nerve. Fortunately the zinc
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EFFECT OF SPIRONOLACTONE ON BLOOD
BILE-ACID LEVELS
SIR,&mdash;Patients with liver and bileduct diseases often have
raised blood bile-acid levels and consequent symptoms such as
pruritus. Treatment with cholestyramine, neomycin, or a bar-
biturate may lower the high plasma bile-acid concentration,
but their application is limited by side-effects. Cholestyramine,
the anion exchange resin, which decreases bile-acid levels by
accelerating fxcal excretion,S may cause diarrhcea, stea-
torrhrea, and loss of fat-soluble vitamins. Polybasic antibiotics,
such as neomycin, which lower bile-acid levels by the forma-
tion of insoluble precipitates,6 may induce a malabsorption
syndrome with mucosal changes in the bowel. Phenobarbitone
in large doses reduces plasma bile-acid concentration, possibly
through enzyme inductive effects,’ but many patients suffer
from excessive sedation.
Solymoss et al.8 and Szeber&eacute;nyi and Fekete9 have shown
that spironolactone is a potent microsomal enzyme inducer
and can accelerate the metabolism of various drugs. We there-
fore suggested that spironolactone might also reduce raised
bile-acid levels and might do so without serious side-effects.
Eleven patients with a diagnosis of liver cirrhosis and four
with various forms of bileduct obstruction received spironolac-
1. Kay, R G., Tasman-Jones, C. Lancet, 1975, ii, 605.
2. ibid 1975, ii, 351.
3 Moynahan, E. J. ibid. 1976, i, 91.
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5 Moore, R B., Crane, C. A., Frantz, I. D., Jr. J. clin. Invest. 1968, 47, 1664.
6 Eyssen, H, Evrard, E., Vanderhaeghe, H. J. Lab. clin. Med. 1966, 68, 753.
7 Redringer, R N , Small, D. M. J. clin. Invest. 1973, 52, 161.
8 Solymouss, B., Classen, H. G., Varga, S. Proc. Soc. exp. Biol. Med. 1969,
132, 940.
9 Szeber&eacute;nvi, S., Fekete, G. Expta. med. Int. Congr. Ser. 1970, no. 210, p. 182




tone (’Verospiron’, Richter, Budapest) 200 mg/d by mouth for
4 to 14 days. Levels of cholic, chenodeoxycholic, and deoxy-
cholic acids were determined by our spectrofluorimetric
method6 before and on the last day of treatment. The sum of
the values of the metabolites were recorded (see accompanying
table). The normal fasting bile-acid level in our previous
study’" was between 89 and 157 (average 116), &micro;g/dl. After
spironolactone a sharp fall from 545 to 240 &micro;g/dl was observed
in patients with hepatobiliary diseases. Spironolactone did not
affect the normal plasma bile-acid level of 8 control subjects.
Patients with liver disease, mostly those with cirrhosis, often
receive spironolactone as a diuretic. Our observations suggest
that spironolactone is indicated for patients with cirrhosis who
are not already on it and have raised plasma bile-acid concen-
trations. Spironolactone also seems to be indicated in mtra-
hepatic cholestasis and possibly in other hepatobiliary diseases
with high plasma bile-acid levels.
First Department of Medicine,
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Obituary
STEPHEN HENRY BRUNTON BLAIKIE
T.D., M.B.Edin., F.R.C.P.E.
Dr Stephen Blaikie, who had been in general practice
in Knightsbridge for the past 25 years, died on June 4
at the age of 59.
After Uppingham, he started his medical training at the
University of Edinburgh, but before it was completed he left
to join the Royal Scots, later transferring to the Parachute
Regiment, of which he came to command the 4th Battalion.
Wounded in Italy, he was invalided home and resumed his
training at Edinburgh. He rapidly qualified and after house-
appointments at the Royal Infirmary, in 1947 he became
M.R.C.P.E. and started in general practice in London. His
father, who had been a well-known and much-loved general
practitioner in Brook Street, died before his son had qualified.
There was, therefore, no direct succession, and Stephen
Blaikie’s early years in London were spent as an assistant to
Dr John Hunt (now Lord Hunt of Fawley). He became
F.R.C.P.E. in 1972.
Stephen Blaikie’s grace and distinction, combined with his
formidable professional attainments, ensured his immediate
success in general practice. For over a quarter of a century he
held a leading place amongst the family doctors of the West
End of London. His charm, his compassion, and his gaiety won
the devotion of the numberless patients who entrusted them-
selves to his care. His scrupulous professional standards and
his outstanding ability endeared him to his colleagues, both
general practitioners and consultants, He exemplified all that
was best of the traditional British family doctor. There will be
many patients who feel not only a sense of personal bereave-
ment at his passing but also an irreparable loss at being
